Physician profile
Robin L Travers
NPI 1578532388
$6,888.56
in general payments reported to CMS, 2019-2025
30 companies · $1,100 in 2025
The $1,100 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $884 · 2020: $499 · 2021: $1,084 · 2022: $1,170 · 2023: $1,153 · 2024: $1,000 · 2025: $1,100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,252.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $902.22 | 2019-2025 | Rinvoq, Skyrizi |
| Leo Pharma INC. | $796.21 | 2019-2025 | Adbry, Anzupgo |
| Ucb, INC. | $521.72 | 2019-2025 | Bimzelx, Cimzia |
| Amgen INC. | $517.79 | 2019-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $440.70 | 2019-2025 | |
| Lilly USA, LLC | $424.52 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Janssen Biotech, INC. | $327.29 | 2019-2025 | Tremfya |
| Genzyme Corporation | $314.38 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $309.82 | 2019-2025 | Absorica Ld, Winlevi |
| E.R. Squibb & Sons, L.L.C. | $296.08 | 2022-2025 | Sotyktu |
| Incyte Corporation | $278.79 | 2021-2025 | Opzelura |
| Pfizer INC. | $277.15 | 2019-2024 | |
| Galderma Laboratories, L.P. | $264.31 | 2019-2025 | Aklief, Nemluvio, Epsolay |
| Regeneron Healthcare Solutions, INC. | $164.64 | 2019-2025 | Dupixent, Libtayo |
| Genentech USA, INC. | $156.75 | 2019-2024 | Xolair |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $135.10 | 2023-2024 | Vtama |
| Allergan, INC. | $105.52 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $97.14 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.80 | 2023-2024 | Spevigo |
| Celgene Corporation | $86.66 | 2019 | |
| Arcutis Biotherapeutics, INC. | $82.36 | 2023-2025 | Zoryve |
| Organon LLC | $65.24 | 2025 | Vtama |
| Mission Pharmacal Company | $45.60 | 2019 | |
| Averitas Pharma INC. | $33.31 | 2023 | Qutenza |
| Mylan Pharmaceuticals INC. | $33.25 | 2019 | |
| Revance Therapeutics, INC. | $27.01 | 2024 | Daxxify |
| Dermira, INC. | $24.52 | 2019 | |
| Mayne Pharma Commercial LLC | $23.10 | 2019 | |
| Aclaris Therapeutics, INC. | $22.14 | 2019 | |
| Botanix Sb INC | $19.44 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Travers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.